Clinical features and autonomic testing predict survival in multiple system atrophy.

Area of Science:

• Neurology
• Autonomic Neuroscience
• Clinical Research

Background:

• Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic dysfunction and motor symptoms (parkinsonism or ataxia).
• Predictors of survival in MSA are not fully established, with varying reports on the influence of clinical features.
• Objective autonomic testing is crucial for MSA diagnosis and may offer prognostic insights.

Purpose of the Study:

• To evaluate overall survival in a large cohort of patients with multiple system atrophy (MSA).
• To identify clinical and autonomic predictors of survival in MSA patients.
• To assess the prognostic value of objective autonomic testing in MSA.

Main Methods:

• Retrospective review of 685 patients with probable or possible MSA evaluated at Mayo Clinic (1998-2012).
• Analysis included clinical data and results from autonomic reflex screening.
• Statistical analysis, including univariate and multivariate models, was used to identify survival predictors.

Main Results:

• Median survival from symptom onset to death was 7.51 years; from diagnosis to death was 3.33 years.
• No significant difference in survival was observed between MSA-parkinsonism and MSA-cerebellar ataxia subtypes.
• Unfavorable survival predictors included falls, bladder symptoms, urinary catheterization, orthostatic intolerance, older age of onset, and higher autonomic severity score.

Conclusions:

• Clinical features, such as falls and bladder symptoms, are significant predictors of survival in MSA.
• Objective autonomic testing provides an independent prognostic marker for survival in MSA patients.
• These findings highlight the utility of clinical assessment and autonomic testing for predicting MSA patient outcomes.